{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:05:55Z","timestamp":1794668755655,"version":"4.9.1"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Diabetic retinopathy (DR) is a leading cause of acquired blindness. Retinal non-perfusion (RNP) is associated with DR worsening and vision loss. There are no treatments available that specifically address RNP in DR. The semaphorin 3A (Sema3A)\/neuropilin 1 (Nrp1) pathway may be involved in RNP progression in DR. In DR, capillary dropout leads to RNP, subsequent hypoxia and ischaemia. Upon chronic hypoxia, retinal cells produce various factors, including vascular endothelial growth factor (VEGF) and Sema3A. While VEGF promotes the growth of new vessels, elevated Sema3A forms a chemical barrier in the retina that directs new blood vessels away from the ischaemic retina. The imbalance of VEGF and Sema3A in DR is believed to dysregulate physiological revascularisation in the retina and may guide blood vessels away from ischaemic regions into the vitreous cavity, causing the pathological neovascularisation typically found in advanced DR. Approved treatments can improve DR severity, but do not appear to improve the underlying RNP. This may lead to a high treatment burden over time and a risk for disease worsening once therapy is stopped, as the underlying disease may progress despite treatment. Therapeutic agents targeting the Sema3A\/Nrp1 pathway may have the potential to improve RNP as a core pathophysiologic aspect of DR. This potential disease-modifying effect may sustainably improve DR and preserve the patient\u2019s visual function and quality of life. This review summarises Sema3A\/Nrp1 pathway involvement in DR and RNP and its role as a potential target to treat DR in the context of current treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method oF Literature Search<\/jats:title>\n                    <jats:p>Background literature was searched in PubMed using search terms such as \u2018diabetic retinopathy\u2019, \u2018diabetic macular ischemia\u2019, \u2018diabetic macular edema\u2019, \u2018semaphorin 3a\u2019, \u2018neuropilin 1\u2019, \u2018retinal non-perfusion\u2019, \u2018vascular perfusion\u2019, \u2018anti-VEGF\u2019, \u2018corticosteroid\u2019 and \u2018laser photocoagulation\u2019. Selected articles in English included the following publication types: Clinical Study; Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Clinical Trial Protocol; Controlled Clinical Trial; Meta-Analysis, Randomised Controlled Trial; Review; and Systematic Review. Reference lists from the selected articles were also reviewed, from which relevant articles were manually included into the final list, in addition to extensive general background reading about the topic. Additionally, ClinicalTrials.gov and Google searches were performed to identify upcoming trials of treatments in DR with the potential to improve RNP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Plain Language Summary<\/jats:title>\n                    <jats:p>The retina is the light-sensing layer at the back of the eye. Damage to the retina can lead to eye diseases. Diabetes can cause reduced blood flow to the retina, damaging the retina and leading to vision loss. Eye disease is common in people with diabetes. This review discusses different drugs currently used to treat sight loss in people with diabetes. Taking some of these drugs can affect the quality of a person\u2019s life. For example, the treatment may need to be given by regular injections into the eye and\/or may have upsetting side effects. This review also talks about new drugs now being studied to improve blood flow to the retina and slow or stop sight loss in people with diabetes. Proteins called semaphorin 3A and neuropilin 1 regulate blood flow to the retina. New drugs have been made that work against these proteins. These drugs may help to increase blood flow to the retina. Several other drugs that may increase blood flow to the retina are also being studied in animals and humans.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-025-03835-w","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:44:06Z","timestamp":1752137046000},"page":"3209-3217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["New targets in diabetic retinopathy: addressing limitations of current treatments through the Sema3A\/Nrp1 pathway"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8952-0659","authenticated-orcid":false,"given":"Sobha","family":"Sivaprasad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3358-3516","authenticated-orcid":false,"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gliem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7756-5091","authenticated-orcid":false,"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Zippel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6024-8441","authenticated-orcid":false,"given":"Quan","family":"Dong Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"3835_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","volume":"2","author":"R Lee","year":"2015","unstructured":"Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis. 2015;2:17.","journal-title":"Eye Vis"},{"key":"3835_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.visres.2017.04.003","volume":"139","author":"J Lechner","year":"2017","unstructured":"Lechner J, O\u2019Leary OE, Stitt AW. The pathology associated with diabetic retinopathy. Vision Res. 2017;139:7\u201314.","journal-title":"Vision Res"},{"key":"3835_CR3","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.drudis.2019.03.028","volume":"24","author":"N Dulull","year":"2019","unstructured":"Dulull N, Kwa F, Osman N, Rai U, Shaikh B, Thrimawithana TR. Recent advances in the management of diabetic retinopathy. Drug Discov Today. 2019;24:1499\u2013509.","journal-title":"Drug Discov Today"},{"key":"3835_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41433-021-01649-0","volume":"36","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Yu HJ, Avery RL, Ehlers JP, Tadayoni R, Sadda SR. Retinal non-perfusion in diabetic retinopathy. Eye. 2022;36:249\u201356.","journal-title":"Eye"},{"key":"3835_CR5","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S0161-6420(81)34983-5","volume":"88","author":"K Shimizu","year":"1981","unstructured":"Shimizu K, Kobayashi Y, Muraoka K. Midperipheral fundus involvement in diabetic retinopathy. Ophthalmology. 1981;88:601\u201312.","journal-title":"Ophthalmology"},{"key":"3835_CR6","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1097\/IAE.0000000000003479","volume":"42","author":"PS Silva","year":"2022","unstructured":"Silva PS, Liu D, Glassman AR, Aiello LP, Grover S, Kingsley RM, et al. Assessment of fluorescein angiography nonperfusion in eyes with diabetic retinopathy using ultrawide field retinal imaging. Retina. 2022;42:1302\u201310.","journal-title":"Retina"},{"key":"3835_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/iovs.62.13.1","volume":"62","author":"F Datlinger","year":"2021","unstructured":"Datlinger F, Wassermann L, Reumueller A, Hajdu D, Steiner I, Salas M, et al. Assessment of detailed photoreceptor structure and retinal sensitivity in diabetic macular ischemia using adaptive optics-OCT and microperimetry. Investig Ophthalmol Vis Sci. 2021;62:1.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"3835_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1167\/iovs.62.1.9","volume":"62","author":"ASH Tsai","year":"2021","unstructured":"Tsai ASH, Jordan-Yu JM, Gan ATL, Teo KYC, Tan GSW, Lee SY, et al. Diabetic macular ischemia: influence of optical coherence tomography angiography parameters on changes in functional outcomes over one year. Investig Ophthalmol Vis Sci. 2021;62:9.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"3835_CR9","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.3390\/jcm12062406","volume":"12","author":"AA Mohite","year":"2023","unstructured":"Mohite AA, Perais JA, McCullough P, Lois N. Retinal ischaemia in diabetic retinopathy: understanding and overcoming a therapeutic challenge. J Clin Med. 2023;12:2406.","journal-title":"J Clin Med"},{"key":"3835_CR10","doi-asserted-by":"publisher","first-page":"1125062","DOI":"10.3389\/fmed.2023.1125062","volume":"10","author":"A Antropoli","year":"2023","unstructured":"Antropoli A, Arrigo A, La Franca L, Bianco L, Barlocci E, Fusi E, et al. Peripheral and central capillary non-perfusion in diabetic retinopathy: an updated overview. Front Med. 2023;10:1125062.","journal-title":"Front Med"},{"key":"3835_CR11","doi-asserted-by":"publisher","first-page":"100267","DOI":"10.1016\/j.xops.2022.100267","volume":"3","author":"M Battaglia Parodi","year":"2023","unstructured":"Battaglia Parodi M, Arrigo A, Antropoli A, Bianco L, Saladino A, Bandello F, et al. Deep capillary plexus as biomarker of peripheral capillary nonperfusion in central retinal vein occlusion. Ophthalmol Sci. 2023;3:100267.","journal-title":"Ophthalmol Sci"},{"key":"3835_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1167\/tvst.7.4.4","volume":"7","author":"BD Krawitz","year":"2018","unstructured":"Krawitz BD, Phillips E, Bavier RD, Mo S, Carroll J, Rosen RB, et al. Parafoveal nonperfusion analysis in diabetic retinopathy using optical coherence tomography angiography. Transl Vis Sci Technol. 2018;7:4.","journal-title":"Transl Vis Sci Technol"},{"key":"3835_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.oret.2017.09.007","volume":"1","author":"JP Ehlers","year":"2017","unstructured":"Ehlers JP. The OCT angiography revolution: 5 emerging themes. Ophthalmol Retina. 2017;1:457\u201360.","journal-title":"Ophthalmol Retina"},{"key":"3835_CR14","first-page":"46","volume":"7","author":"C Or","year":"2018","unstructured":"Or C, Sabrosa AS, Sorour O, Arya M, Waheed N. Use of OCTA, FA, and ultra-widefield imaging in quantifying retinal ischemia: a review. Asia Pac J Ophthalmol. 2018;7:46\u201351.","journal-title":"Asia Pac J Ophthalmol"},{"key":"3835_CR15","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1038\/s41433-024-02989-3","volume":"38","author":"S Vujosevic","year":"2024","unstructured":"Vujosevic S, Fantaguzzi F, Silva PS, Salongcay R, Brambilla M, Torti E, et al. Macula vs periphery in diabetic retinopathy: OCT-angiography and ultrawide field fluorescein angiography imaging of retinal non perfusion. Eye. 2024;38:1668\u201373.","journal-title":"Eye"},{"key":"3835_CR16","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3389\/fimmu.2020.00346","volume":"11","author":"V Iragavarapu-Charyulu","year":"2020","unstructured":"Iragavarapu-Charyulu V, Wojcikiewicz E, Urdaneta A. Semaphorins in angiogenesis and autoimmune diseases: therapeutic targets? Front Immunol. 2020;11:346.","journal-title":"Front Immunol"},{"key":"3835_CR17","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.1182\/blood-2010-10-311589","volume":"117","author":"JS Joyal","year":"2011","unstructured":"Joyal JS, Sitaras N, Binet F, Rivera JC, Stahl A, Zaniolo K, et al. Ischemic neurons prevent vascular regeneration of neural tissue by secreting semaphorin 3A. Blood. 2011;117:6024\u201335.","journal-title":"Blood"},{"key":"3835_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.preteyeres.2016.02.003","volume":"52","author":"C Raimondi","year":"2016","unstructured":"Raimondi C, Brash JT, Fantin A, Ruhrberg C. NRP1 function and targeting in neurovascular development and eye disease. Prog Retin Eye Res. 2016;52:64\u201383.","journal-title":"Prog Retin Eye Res"},{"key":"3835_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrn3723","volume":"15","author":"D Goldman","year":"2014","unstructured":"Goldman D. M\u00fcller glial cell reprogramming and retina regeneration. Nat Rev Neurosci. 2014;15:431\u201342.","journal-title":"Nat Rev Neurosci"},{"key":"3835_CR20","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1242\/dev.127670","volume":"143","author":"AM Ochsenbein","year":"2016","unstructured":"Ochsenbein AM, Karaman S, Proulx ST, Berchtold M, Jurisic G, Stoeckli ET, et al. Endothelial cell-derived semaphorin 3A inhibits filopodia formation by blood vascular tip cells. Development. 2016;143:589\u201394.","journal-title":"Development"},{"key":"3835_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-6448-2_1","volume":"1493","author":"LT Alto","year":"2017","unstructured":"Alto LT, Terman JR. Semaphorins and their signaling mechanisms. Methods Mol Biol. 2017;1493:1\u201325.","journal-title":"Methods Mol Biol"},{"key":"3835_CR22","doi-asserted-by":"publisher","first-page":"111329","DOI":"10.1016\/j.biopha.2021.111329","volume":"137","author":"B Jiao","year":"2021","unstructured":"Jiao B, Liu S, Tan X, Lu P, Wang D, Xu H. Class-3 semaphorins: potent multifunctional modulators for angiogenesis-associated diseases. Biomed Pharmacother. 2021;137:111329.","journal-title":"Biomed Pharmacother"},{"key":"3835_CR23","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1172\/JCI76492","volume":"124","author":"A Dejda","year":"2014","unstructured":"Dejda A, Mawambo G, Cerani A, Miloudi K, Shao Z, Daudelin JF, et al. Neuropilin-1 mediates myeloid cell chemoattraction and influences retinal neuroimmune crosstalk. J Clin Investig. 2014;124:4807\u201322.","journal-title":"J Clin Investig"},{"key":"3835_CR24","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3892\/ol.2014.1920","volume":"7","author":"H Zhou","year":"2014","unstructured":"Zhou H, Wu A, Fu W, Lv Z, Zhang Z. Significance of semaphorin-3A and MMP-14 protein expression in non-small cell lung cancer. Oncol Lett. 2014;7:1395\u2013400.","journal-title":"Oncol Lett"},{"key":"3835_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1158\/1538-7445.AM2019-66","volume":"79","author":"TV Tellman","year":"2019","unstructured":"Tellman TV, Cruz LA, Grindel BJ, Chung LWK, Farach-Carson MC. MMP-7 cleavage of the perlecan-Sema3A-plexin(A1)-neuropilin-1 complex promotes the progression of metastatic prostate cancer. Cancer Res. 2019;79:66.","journal-title":"Cancer Res"},{"key":"3835_CR26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3390\/diabetology3010011","volume":"3","author":"P Ansari","year":"2022","unstructured":"Ansari P, Tabasumma N, Snigdha NN, Siam NH, Panduru RVNRS, Azam S, et al. Diabetic retinopathy: an overview on mechanisms, pathophysiology and pharmacotherapy. Diabetology. 2022;3:159\u201375.","journal-title":"Diabetology"},{"key":"3835_CR27","doi-asserted-by":"publisher","first-page":"101799","DOI":"10.1016\/j.redox.2020.101799","volume":"37","author":"Q Kang","year":"2020","unstructured":"Kang Q, Yang C. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020;37:101799.","journal-title":"Redox Biol"},{"key":"3835_CR28","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.cmet.2013.09.003","volume":"18","author":"A Cerani","year":"2013","unstructured":"Cerani A, Tetreault N, Menard C, Lapalme E, Patel C, Sitaras N, et al. Neuron-derived semaphorin 3A is an early inducer of vascular permeability in diabetic retinopathy via neuropilin-1. Cell Metab. 2013;18:505\u201318.","journal-title":"Cell Metab"},{"key":"3835_CR29","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.ajpath.2020.04.011","volume":"190","author":"TH Khanh Vu","year":"2020","unstructured":"Khanh Vu TH, Chen H, Pan L, Cho KS, Doesburg D, Thee EF, et al. CD4(+) T-cell responses mediate progressive neurodegeneration in experimental ischemic retinopathy. Am J Pathol. 2020;190:1723\u201334.","journal-title":"Am J Pathol"},{"key":"3835_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03190-9","volume":"21","author":"L Zhou","year":"2024","unstructured":"Zhou L, Xu Z, Lu H, Cho H, Xie Y, Lee G, et al. Suppression of inner blood-retinal barrier breakdown and pathogenic M\u00fcller glia activation in ischemia retinopathy by myeloid cell depletion. J Neuroinflamm. 2024;21:210.","journal-title":"J Neuroinflamm"},{"key":"3835_CR31","first-page":"e3064","volume":"10","author":"M Usman","year":"2018","unstructured":"Usman M. An overview of our current understanding of diabetic macular ischemia (DMI). Cureus. 2018;10:e3064.","journal-title":"Cureus"},{"key":"3835_CR32","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1242\/dev.103028","volume":"141","author":"A Fantin","year":"2014","unstructured":"Fantin A, Herzog B, Mahmoud M, Yamaji M, Plein A, Denti L, et al. Neuropilin 1 (NRP1) hypomorphism combined with defective VEGF-A binding reveals novel roles for NRP1 in developmental and pathological angiogenesis. Development. 2014;141:556\u201362.","journal-title":"Development"},{"key":"3835_CR33","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1124\/jpet.122.001473","volume":"385","author":"L Thomas","year":"2023","unstructured":"Thomas L, Low S, Hansen G, Bakker RA, Zippel N. BI-Y, an neuropilin-1 antagonist, enhances revascularization and prevents vascular endothelial growth factor-A induced retinal hyperpermeability in rodent models of retinopathies. J Pharmacol Exp Ther. 2023;385:214\u201321.","journal-title":"J Pharmacol Exp Ther"},{"key":"3835_CR34","doi-asserted-by":"publisher","first-page":"e0169865","DOI":"10.1371\/journal.pone.0169865","volume":"12","author":"P Fern\u00e1ndez-Robredo","year":"2017","unstructured":"Fern\u00e1ndez-Robredo P, Selvam S, Powner MB, Sim DA, Fruttiger M. Neuropilin 1 involvement in choroidal and retinal neovascularisation. PLoS ONE. 2017;12:e0169865.","journal-title":"PLoS ONE"},{"key":"3835_CR35","first-page":"1649","volume":"41","author":"S Ishida","year":"2000","unstructured":"Ishida S, Shinoda K, Kawashima S, Oguchi Y, Okada Y, Ikeda E. Coexpression of VEGF receptors VEGF-R2 and neuropilin-1 in proliferative diabetic retinopathy. Investig Ophthalmol Vis Sci. 2000;41:1649\u201356.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"3835_CR36","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1167\/iovs.16-19468","volume":"57","author":"SH Kwon","year":"2016","unstructured":"Kwon SH, Shin JP, Kim IT, Park DH. Association of plasma semaphorin 3A with phenotypes of diabetic retinopathy and nephropathy. Investig Ophthalmol Vis Sci. 2016;57:2983\u20139.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"3835_CR37","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ajo.2020.01.024","volume":"213","author":"JF Russell","year":"2020","unstructured":"Russell JF, Al-Khersan H, Shi Y, Scott NL, Hinkle JW, Fan KC, et al. Retinal nonperfusion in proliferative diabetic retinopathy before and after panretinal photocoagulation assessed by widefield OCT angiography. Am J Ophthalmol. 2020;213:177\u201385.","journal-title":"Am J Ophthalmol"},{"key":"3835_CR38","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3390\/life13051098","volume":"13","author":"TA Bahr","year":"2023","unstructured":"Bahr TA, Bakri SJ. Update on the management of diabetic retinopathy: anti-VEGF agents for the prevention of complications and progression of nonproliferative and proliferative retinopathy. Life. 2023;13:1098.","journal-title":"Life"},{"key":"3835_CR39","unstructured":"Genentech Inc. LUCENTIS\u00ae (ranibizumab) for intravitreal injection. Prescribing information. 2024; https:\/\/www.gene.com\/download\/pdf\/lucentis_prescribing.pdf."},{"key":"3835_CR40","unstructured":"Regeneron Pharmaceuticals Inc. EYLEA\u00ae (aflibercept) injection, for intravitreal use. Prescribing information. 2023; https:\/\/www.regeneron.com\/downloads\/eylea_fpi.pdf."},{"key":"3835_CR41","unstructured":"Genentech Inc. VABYSMO\u00ae (faricimab-svoa) injection, for intravitreal use. Prescribing information. 2024; https:\/\/www.gene.com\/download\/pdf\/vabysmo_prescribing.pdf."},{"key":"3835_CR42","unstructured":"Novartis Pharmaceuticals Corporation. BEOVU\u00ae (brolucizumab-dbll) injection, for intravitreal use. Prescribing information. 2024; https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/beovu.pdf."},{"key":"3835_CR43","first-page":"188","volume":"15","author":"AG Elnahry","year":"2020","unstructured":"Elnahry AG, Abdel-Kader AA, Habib AE, Elnahry GA, Raafat KA, Elrakhawy K. Review on recent trials evaluating the effect of intravitreal injections of anti-VEGF agents on the macular perfusion of diabetic patients with diabetic macular edema. Rev Recent Clin Trials. 2020;15:188\u201398.","journal-title":"Rev Recent Clin Trials"},{"key":"3835_CR44","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/s41433-021-01750-4","volume":"36","author":"I Chatziralli","year":"2022","unstructured":"Chatziralli I, Touhami S, Cicinelli MV, Agapitou C, Dimitriou E, Theodossiadis G, et al. Disentangling the association between retinal non-perfusion and anti-VEGF agents in diabetic retinopathy. Eye. 2022;36:692\u2013703.","journal-title":"Eye"},{"key":"3835_CR45","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.ophtha.2014.03.021","volume":"121","author":"PA Campochiaro","year":"2014","unstructured":"Campochiaro PA, Wykoff CC, Shapiro H, Rubio RG, Ehrlich JS. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology. 2014;121:1783\u20139.","journal-title":"Ophthalmology"},{"key":"3835_CR46","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jamaophthalmol.2017.6135","volume":"136","author":"SG Karst","year":"2018","unstructured":"Karst SG, Deak GG, Gerendas BS, Waldstein SM, Lammer J, Simader C, et al. Association of changes in macular perfusion with ranibizumab treatment for diabetic macular edema: a subanalysis of the RESTORE (extension) study. JAMA Ophthalmol. 2018;136:315\u201321.","journal-title":"JAMA Ophthalmol"},{"key":"3835_CR47","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.ophtha.2019.03.040","volume":"126","author":"CC Wykoff","year":"2019","unstructured":"Wykoff CC, Shah C, Dhoot D, Coleman HR, Thompson D, Du W, et al. Longitudinal retinal perfusion status in eyes with diabetic macular edema receiving intravitreal aflibercept or laser in VISTA study. Ophthalmology. 2019;126:1171\u201380.","journal-title":"Ophthalmology"},{"key":"3835_CR48","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1167\/iovs.17-23509","volume":"59","author":"L Nicholson","year":"2018","unstructured":"Nicholson L, Crosby-Nwaobi R, Vasconcelos JC, Prevost AT, Ramu J, Riddell A, et al. Mechanistic evaluation of panretinal photocoagulation versus aflibercept in proliferative diabetic retinopathy: CLARITY substudy. Investig Ophthalmol Vis Sci. 2018;59:4277\u201384.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"3835_CR49","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.oret.2022.02.013","volume":"6","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Nittala MG, Villanueva Boone C, Yu HJ, Fan W, Velaga SB, et al. Final outcomes from the randomized RECOVERY trial of aflibercept for retinal nonperfusion in proliferative diabetic retinopathy. Ophthalmol Retina. 2022;6:557\u201366.","journal-title":"Ophthalmol Retina"},{"key":"3835_CR50","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.oret.2019.07.011","volume":"3","author":"CC Wykoff","year":"2019","unstructured":"Wykoff CC, Nittala MG, Zhou B, Fan W, Velaga SB, Lampen SIR, et al. Intravitreal aflibercept for retinal nonperfusion in proliferative diabetic retinopathy: outcomes from the randomized RECOVERY trial. Ophthalmol Retina. 2019;3:1076\u201386.","journal-title":"Ophthalmol Retina"},{"key":"3835_CR51","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1111\/aos.15673","volume":"102","author":"K Nanji","year":"2024","unstructured":"Nanji K, Sarohia GS, Xie J, Patil NS, Phillips M, Zeraatkar D, et al. Anti-vascular endothelial growth factor therapy and retinal non-perfusion in diabetic retinopathy: a meta-analysis of randomised trials. Acta Ophthalmol. 2024;102:e31\u201341.","journal-title":"Acta Ophthalmol"},{"key":"3835_CR52","doi-asserted-by":"publisher","first-page":"e000696","DOI":"10.1136\/bmjophth-2020-000696","volume":"6","author":"L Downey","year":"2021","unstructured":"Downey L, Acharya N, Devonport H, Gale R, Habib M, Manjunath V, et al. Treatment choices for diabetic macular oedema: a guideline for when to consider an intravitreal corticosteroid, including adaptations for the COVID-19 era. BMJ Open Ophthalmol. 2021;6:e000696.","journal-title":"BMJ Open Ophthalmol"},{"key":"3835_CR53","first-page":"Cd005656","volume":"11","author":"T Rittiphairoj","year":"2020","unstructured":"Rittiphairoj T, Mir TA, Li T, Virgili G. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2020;11:Cd005656.","journal-title":"Cochrane Database Syst Rev"},{"key":"3835_CR54","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.ophtha.2016.11.034","volume":"124","author":"CC Wykoff","year":"2017","unstructured":"Wykoff CC, Chakravarthy U, Campochiaro PA, Bailey C, Green K, Cunha-Vaz J. Long-term effects of intravitreal 0.19 mg fluocinolone acetonide implant on progression and regression of diabetic retinopathy. Ophthalmology. 2017;124:440\u20139.","journal-title":"Ophthalmology"},{"key":"3835_CR55","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00592-018-1117-z","volume":"55","author":"M Iglicki","year":"2018","unstructured":"Iglicki M, Zur D, Busch C, Okada M, Loewenstein A. Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the \u2018DR-Pro-DEX Study\u2019. Acta Diabetol. 2018;55:541\u20137.","journal-title":"Acta Diabetol"},{"key":"3835_CR56","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3928\/23258160-20230221-02","volume":"54","author":"NC Capelanes","year":"2023","unstructured":"Capelanes NC, Malerbi FK, Novais EA, Regatieri CVS. Optical coherence tomography angiographic evaluation of macular vessel density in diabetic macular edema after intravitreal dexamethasone implants: a prospective interventional trial. Ophthalmic Surg Lasers Imaging Retina. 2023;54:174\u201382.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"3835_CR57","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40123-022-00455-5","volume":"11","author":"M Brambati","year":"2022","unstructured":"Brambati M, Borrelli E, Capone L, Querques L, Sacconi R, Battista M, et al. Changes in macular perfusion after ILUVIEN\u00ae intravitreal implant for diabetic macular edema: an OCTA study. Ophthalmol Ther. 2022;11:653\u201360.","journal-title":"Ophthalmol Ther"},{"key":"3835_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2017.11.003","volume":"64","author":"RF Spaide","year":"2018","unstructured":"Spaide RF, Fujimoto JG, Waheed NK, Sadda SR, Staurenghi G. Optical coherence tomography angiography. Prog Retin Eye Res. 2018;64:1\u201355.","journal-title":"Prog Retin Eye Res"},{"key":"3835_CR59","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00592-019-01435-1","volume":"57","author":"E Borrelli","year":"2020","unstructured":"Borrelli E, Parravano M, Querques L, Sacconi R, Giorno P, De Geronimo D, et al. One-year follow-up of ischemic index changes after intravitreal dexamethasone implant for diabetic macular edema: an ultra-widefield fluorescein angiography study. Acta Diabetol. 2020;57:543\u201348.","journal-title":"Acta Diabetol"},{"key":"3835_CR60","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2147\/OPTH.S345947","volume":"16","author":"P Carnota-M\u00e9ndez","year":"2022","unstructured":"Carnota-M\u00e9ndez P, M\u00e9ndez-V\u00e1zquez C, P\u00e9rez-Gavela C. OCT-angiography changes in patients with diabetic macular edema treated with intravitreal dexamethasone implant. Clin Ophthalmol. 2022;16:247\u201363.","journal-title":"Clin Ophthalmol"},{"key":"3835_CR61","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00592-019-01424-4","volume":"57","author":"S Vujosevic","year":"2020","unstructured":"Vujosevic S, Toma C, Villani E, Muraca A, Torti E, Florimbi G, et al. Diabetic macular edema with neuroretinal detachment: OCT and OCT-angiography biomarkers of treatment response to anti-VEGF and steroids. Acta Diabetol. 2020;57:287\u201396.","journal-title":"Acta Diabetol"},{"key":"3835_CR62","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.ophtha.2018.04.007","volume":"125","author":"TY Wong","year":"2018","unstructured":"Wong TY, Sun J, Kawasaki R, Ruamviboonsuk P, Gupta N, Lansingh VC, et al. Guidelines on diabetic eye care: The International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology. 2018;125:1608\u201322.","journal-title":"Ophthalmology"},{"key":"3835_CR63","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/08820538.2017.1353820","volume":"33","author":"SV Reddy","year":"2018","unstructured":"Reddy SV, Husain D. Panretinal photocoagulation: a review of complications. Semin Ophthalmol. 2018;33:83\u20138.","journal-title":"Semin Ophthalmol"},{"key":"3835_CR64","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0161-6420(81)34978-1","volume":"88","author":"The Diabetic Retinopathy Study Research Group.","year":"1981","unstructured":"The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology. 1981;88:583\u2013600.","journal-title":"Ophthalmology"},{"key":"3835_CR65","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.ophtha.2019.08.010","volume":"128","author":"VH Gonzalez","year":"2021","unstructured":"Gonzalez VH, Wang PW, Ruiz CQ. Panretinal photocoagulation for diabetic retinopathy in the RIDE and RISE trials: not \u201c1 and done\u201d. Ophthalmology. 2021;128:1448\u201357.","journal-title":"Ophthalmology"},{"key":"3835_CR66","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1001\/jamaophthalmol.2018.3255","volume":"136","author":"JG Gross","year":"2018","unstructured":"Gross JG, Glassman AR, Liu D, Sun JK, Antoszyk AN, Baker CW, et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2018;136:1138\u201348.","journal-title":"JAMA Ophthalmol"},{"key":"3835_CR67","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.ophtha.2014.12.001","volume":"122","author":"GE Boynton","year":"2015","unstructured":"Boynton GE, Stem MS, Kwark L, Jackson GR, Farsiu S, Gardner TW. Multimodal characterization of proliferative diabetic retinopathy reveals alterations in outer retinal function and structure. Ophthalmology. 2015;122:957\u201367.","journal-title":"Ophthalmology"},{"key":"3835_CR68","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41433-021-01832-3","volume":"37","author":"T Bro","year":"2023","unstructured":"Bro T, Andersson J. The effects of visual-field loss from panretinal photocoagulation of proliferative diabetic retinopathy on performance in a driving simulator. Eye. 2023;37:103\u20138.","journal-title":"Eye"},{"key":"3835_CR69","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1001\/archophthalmol.2008.565","volume":"127","author":"AJ Brucker","year":"2009","unstructured":"Brucker AJ, Qin H, Antoszyk AN, Beck RW, Bressler NM, Browning DJ, et al. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol. 2009;127:132\u201340.","journal-title":"Arch Ophthalmol"},{"key":"3835_CR70","doi-asserted-by":"publisher","first-page":"8","DOI":"10.25259\/LAJO_4_2023","volume":"6","author":"F Abdi","year":"2023","unstructured":"Abdi F, Daneshtalab A, Gordiz A, Zand A. Complete visual recovery after an inadvertent foveal burn. Lat Am J Ophthalmol. 2023;6:8.","journal-title":"Lat Am J Ophthalmol"},{"key":"3835_CR71","doi-asserted-by":"publisher","first-page":"908","DOI":"10.4103\/ijo.IJO_1433_19","volume":"68","author":"K Kumar","year":"2020","unstructured":"Kumar K, Ganguly A, Sinha TK, Bhattacharya D. Lenticular burns following PASCAL photocoagulation. Indian J Ophthalmol. 2020;68:908\u20139.","journal-title":"Indian J Ophthalmol"},{"key":"3835_CR72","first-page":"2013","volume":"6","author":"M Soman","year":"2012","unstructured":"Soman M, Ganekal S, Nair U, Nair K. Effect of panretinal photocoagulation on macular morphology and thickness in eyes with proliferative diabetic retinopathy without clinically significant macular edema. Clin Ophthalmol. 2012;6:2013\u20137.","journal-title":"Clin Ophthalmol"},{"key":"3835_CR73","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/sj.eye.6701989","volume":"20","author":"WC Wu","year":"2006","unstructured":"Wu WC, Hsu KH, Chen TL, Hwang YS, Lin KK, Li LM, et al. Interventions for relieving pain associated with panretinal photocoagulation: a prospective randomized trial. Eye. 2006;20:712\u20139.","journal-title":"Eye"},{"key":"3835_CR74","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1590\/S0004-27492013000100006","volume":"76","author":"CR Lucena","year":"2013","unstructured":"Lucena CR, Ramos Filho JA, Messias AM, Silva JA, Almeida FP, Scott IU, et al. Panretinal photocoagulation versus intravitreal injection retreatment pain in high-risk proliferative diabetic retinopathy. Arq Bras Oftalmol. 2013;76:18\u201320.","journal-title":"Arq Bras Oftalmol"},{"key":"3835_CR75","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.3390\/medicina58121741","volume":"58","author":"JB Vasilijevi\u0107","year":"2022","unstructured":"Vasilijevi\u0107 JB, Kova\u010devi\u0107 IM, Bukumiri\u0107 ZM, Mari\u0107 GD, Slijep\u010devi\u0107 NA, Pekmezovi\u0107 TD. Vision-related quality of life and treatment satisfaction following panretinal photocoagulation in diabetic retinopathy\u2014a panel study. Medicina. 2022;58:1741.","journal-title":"Medicina"},{"key":"3835_CR76","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1001\/jamaophthalmol.2021.2809","volume":"139","author":"DM Brown","year":"2021","unstructured":"Brown DM, Wykoff CC, Boyer D, Heier JS, Clark WL, Emanuelli A, et al. Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the PANORAMA randomized clinical trial. JAMA Ophthalmol. 2021;139:946\u201355.","journal-title":"JAMA Ophthalmol"},{"key":"3835_CR77","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ophtha.2018.07.027","volume":"126","author":"A Obeid","year":"2019","unstructured":"Obeid A, Su D, Patel SN, Uhr JH, Borkar D, Gao X, et al. Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti-vascular endothelial growth factor. Ophthalmology. 2019;126:407\u201313.","journal-title":"Ophthalmology"},{"key":"3835_CR78","doi-asserted-by":"publisher","first-page":"e001007","DOI":"10.1136\/bmjophth-2022-001007","volume":"7","author":"RA Goldberg","year":"2022","unstructured":"Goldberg RA, Hill L, Davis T, Stoilov I. Effect of less aggressive treatment on diabetic retinopathy severity scale scores: analyses of the RIDE and RISE open-label extension. BMJ Open Ophthalmol. 2022;7:e001007.","journal-title":"BMJ Open Ophthalmol"},{"key":"3835_CR79","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1097\/IAE.0000000000001892","volume":"38","author":"M Weiss","year":"2018","unstructured":"Weiss M, Sim DA, Herold T, Schumann RG, Liegl R, Kern C, et al. Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice. Retina. 2018;38:2293\u2013300.","journal-title":"Retina"},{"key":"3835_CR80","doi-asserted-by":"publisher","first-page":"4610129","DOI":"10.1155\/2018\/4610129","volume":"2018","author":"AL Best","year":"2018","unstructured":"Best AL, Fajnkuchen F, Nghiem-Buffet S, Grenet T, Quentel G, Delahaye-Mazza C, et al. Treatment efficacy and compliance in patients with diabetic macular edema treated with ranibizumab in a real-life setting. J Ophthalmol. 2018;2018:4610129.","journal-title":"J Ophthalmol"},{"key":"3835_CR81","doi-asserted-by":"publisher","first-page":"e001190","DOI":"10.1136\/bmjophth-2022-001190","volume":"8","author":"QD Nguyen","year":"2023","unstructured":"Nguyen QD, Andrew AM, Jennifer IL, Ekaterina P, Ankita C, Rohini R, et al. Simulation of long-term impact of intravitreal anti-VEGF therapy on patients with severe non-proliferative diabetic retinopathy. BMJ Open Ophthalmol. 2023;8:e001190.","journal-title":"BMJ Open Ophthalmol"},{"key":"3835_CR82","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1001\/jama.2022.25029","volume":"329","author":"RK Maturi","year":"2023","unstructured":"Maturi RK, Glassman AR, Josic K, Baker CW, Gerstenblith AT, Jampol LM, et al. Four-year visual outcomes in the protocol W randomized trial of intravitreous aflibercept for prevention of vision-threatening complications of diabetic retinopathy. JAMA. 2023;329:376\u201385.","journal-title":"JAMA"},{"key":"3835_CR83","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2018.02.034","volume":"125","author":"A Obeid","year":"2018","unstructured":"Obeid A, Gao X, Ali FS, Talcott KE, Aderman CM, Hyman L, et al. Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections. Ophthalmology. 2018;125:1386\u201392.","journal-title":"Ophthalmology"},{"key":"3835_CR84","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"KG Falavarjani","year":"2013","unstructured":"Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye. 2013;27:787\u201394.","journal-title":"Eye"},{"key":"3835_CR85","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2147\/OPTH.S100168","volume":"10","author":"S Sivaprasad","year":"2016","unstructured":"Sivaprasad S, Oyetunde S. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol. 2016;10:939\u201346.","journal-title":"Clin Ophthalmol"},{"key":"3835_CR86","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1016\/j.jcjd.2012.07.380","volume":"36","author":"A Cerani","year":"2012","unstructured":"Cerani A, Tetreault N, Binet F, Rezende FA, Sitaras N, Lapalme E, et al. The guidance protein semaphorin3A provokes vascular leakage in diabetic retinopathy. Can J Diabetes. 2012;36:S52.","journal-title":"Can J Diabetes"},{"key":"3835_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06527-y","volume":"23","author":"V Chong","year":"2022","unstructured":"Chong V, Nguyen QD, Sepah Y, Giani A, Pearce E. HORNBILL: a phase I\/IIa trial examining the safety, tolerability and early response of BI 764524 in patients with diabetic retinopathy and diabetic macular ischaemia-rationale, study design and protocol. Trials. 2022;23:669.","journal-title":"Trials"},{"key":"3835_CR88","unstructured":"ClinicalTrials.gov. Phase 2 Spectra study to evaluate the safety and efficacy of OPL-0401 in patients with diabetic retinopathy. 2024; https:\/\/clinicaltrials.gov\/study\/NCT05393284."},{"key":"3835_CR89","unstructured":"Valo Health. Valo Health completes enrollment of OPL-0401 phase 2 study for the treatment of diabetic retinopathy. 2024; https:\/\/www.valohealth.com\/press\/valo-health-completes-enrollment-of-opl-0401-phase-2-study-for-the-treatment-of-diabetic-retinopathy."},{"key":"3835_CR90","unstructured":"Perfuse Therapeutics. Perfuse Therapeutics announces initiation of enrollment to the phase 2a clinical trial of PER001 intravitreal implant in diabetic retinopathy. 2023; https:\/\/perfusetherapeutics.com\/perfuse-therapeutics-announces-initiation-of-enrollment-to-the-phase-2a-clinical-trial-of-per001-intravitreal-implant-in-diabetic-retinopathy\/."},{"key":"3835_CR91","unstructured":"ClinicalTrials.gov. A study of PER-001 in participants with diabetic retinopathy. 2023; https:\/\/clinicaltrials.gov\/study\/NCT06003751."},{"key":"3835_CR92","unstructured":"ClinicalTrials.gov. A study of PER-001 in participants with open-angle glaucoma. 2023; https:\/\/clinicaltrials.gov\/study\/NCT05822245."},{"key":"3835_CR93","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1167\/tvst.11.9.19","volume":"11","author":"H Nguyen","year":"2022","unstructured":"Nguyen H, Chen H, Vuppalapaty M, Whisler E, Logas KR, Sampathkumar P, et al. SZN-413, a FZD4 agonist, as a potential novel therapeutic for the treatment of diabetic retinopathy. Transl Vis Sci Technol. 2022;11:19.","journal-title":"Transl Vis Sci Technol"},{"key":"3835_CR94","first-page":"1163","volume":"62","author":"P Tsuruda","year":"2021","unstructured":"Tsuruda P, Chaney S, Dejda A, Dasgupta S, Crespo-Garcia S, Rao S, et al. UBX1325, a small molecule inhibitor of Bcl-xL, attenuates vascular dysfunction in two animal models of retinopathy. Investig Ophthalmol Vis Sci. 2021;62:1163.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"3835_CR95","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41591-024-02802-4","volume":"30","author":"S Crespo-Garcia","year":"2024","unstructured":"Crespo-Garcia S, Fournier F, Diaz-Marin R, Klier S, Ragusa D, Masaki L, et al. Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial results. Nat Med. 2024;30:443\u201354.","journal-title":"Nat Med"},{"key":"3835_CR96","unstructured":"UNITY Biotechnology. UNITY Biotechnology announces positive 48-week results from phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema. 2023; https:\/\/ir.unitybiotechnology.com\/news-releases\/news-release-details\/unity-biotechnology-announces-positive-48-week-results-phase-2."},{"key":"3835_CR97","unstructured":"UNITY Biotechnology. UNITY Biotechnology announces 48-week results from phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration. 2023; https:\/\/ir.unitybiotechnology.com\/news-releases\/news-release-details\/unity-biotechnology-announces-48-week-results-phase-2-envision."},{"key":"3835_CR98","unstructured":"ClinicalTrials.gov. Safety and efficacy of faricimab in patients with NPDR (MAGIC). 2024; https:\/\/clinicaltrials.gov\/study\/NCT05681884."},{"key":"3835_CR99","unstructured":"Retinal Degeneration Fund. The Retinal Degeneration Fund announces an investment in NVasc. 2023; https:\/\/retinaldegenerationfund.org\/news\/news-posts\/the-retinal-degeneration-fund-announces-an-investment-in-nvasc."},{"key":"3835_CR100","unstructured":"ClinicalTrials.gov. A 2-part study consisting of multiple ascending dose (MAD) safety study, and a dose-finding masked study to assess the safety and efficacy of intravitreal (IVT) EYE103 in patients with diabetic macular edema (DME) or neovascular age-related macular degeneration (NVAMD) (AMARONE). 2023; https:\/\/www.clinicaltrials.gov\/study\/NCT05919693."},{"key":"3835_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-65694-x","volume":"14","author":"P Li","year":"2024","unstructured":"Li P, Wang H, Tian G, Fan Z. Identification of key biomarkers for early warning of diabetic retinopathy using BP neural network algorithm and hierarchical clustering analysis. Sci Rep. 2024;14:15108.","journal-title":"Sci Rep"},{"key":"3835_CR102","doi-asserted-by":"publisher","first-page":"100420","DOI":"10.1016\/j.xops.2023.100420","volume":"4","author":"R Channa","year":"2024","unstructured":"Channa R, Wolf RM, Simo R, Brigell M, Fort P, Curcio C, et al. A new approach to staging diabetic eye disease: staging of diabetic retinal neurodegeneration and diabetic macular edema. Ophthalmol Sci. 2024;4:100420.","journal-title":"Ophthalmol Sci"}],"updated-by":[{"DOI":"10.1038\/s41433-025-03971-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000}}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03835-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03835-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03835-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:02:08Z","timestamp":1764604928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03835-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":102,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3835"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03835-w","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: During the production process the \u201cPlain Language Summary\u201d and \u201cMethod of literature search\u201d have been omitted.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41433-025-03971-3","URL":"https:\/\/doi.org\/10.1038\/s41433-025-03971-3","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SS reports receiving financial support from AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, EyeBiotech, EyePoint Pharmaceuticals, Janssen Pharmaceuticals, Kriya Therapeutics, Novartis, Novo Nordisk, Ocular Therapeutix, OcuTerra, Optos, Roche, Sanofi and Stealth BioTherapeutics. SS was the Editor-in-Chief of the journal Eye at the time of manuscript submission. CMGC reports serving on the safety monitoring committee for diabetic macular ischaemia clinical trials sponsored by Boehringer Ingelheim and receiving financial support from AbbVie, Bayer, Boehringer Ingelheim, Janssen Pharmaceuticals, Novartis, Roche and Zeiss. CMGC is a member of the Eye editorial board. CCW reports receiving consulting fees\/honoraria for ongoing services provided for 4DMT, AbbVie, Adverum, Alcon, Alimera, Alkeus, Allgenesis, AMC Sciences, Annexon, Apellis, Ascidian, Aviceda, Bayer, Biocryst, Bionic Vision, Boehringer Ingelheim, Curacle, Emmecell, EyeBiotech, EyePoint, Genentech, InGel, IVERIC Bio, Janssen, Kiora, Kodiak, Merck, Merit, Nanoscope, Neurotech, NGM, Novartis, Ocular Therapeutix, Ocuphire, OcuTerra, ONL, Opthea, Osanni, Oxular, Perceive Bio, Perfuse, Ray, Regeneron, RegenXBio, Roche, Sandoz, Sanofi, Santen, Stealth, Sylentis, Thea, Therini, Valo, Visgenx and Zeiss; grants for ongoing research support as a Principal Investigator for trials sponsored by 4DMT, Adverum, AffaMed, Alexion, Alimera, Allgenesis, Amgen, Annexin, Annexon, Apellis, Ascidian, Asclepix, Aviceda, Bayer, Boehringer Ingelheim, Chengdu Origen, Clearside, Curacle, EyeBiotech, EyePoint, Genentech, Gyroscope, IONIS, iRENIX, IVERIC bio, Janssen, Kodiak, Kyoto DDD, Kyowa Kirin, Nanoscope, Neurotech, NGM, Novartis, Ocugen, Ocular Therapeutix, OcuTerra, OliX, Opthea, Outlook Therapeutics, Oxular, Oxurion, Perceive Bio, Pykus, Regeneron, RegenXBio, Rezolute, Roche, Shanghai Henlius, Stealth, Skyline and Valo; and stock investments in InGel, ONL, Osanni, Panther, PolyPhotonix, RecensMedical, TissueGen, Visgenx and Vitranu. SI reports receiving financial support from AbbVie, Alcon, Alpha Communications, AMO Japan, Bayer, Bloom Technology, Bonac, Chugai, HOYA, Kowa, Kyowa Kirin, Mylan, Nidec, Nippon Boehringer Ingelheim, Novartis, Otsuka, Santen, Seed, Senju and Wakamoto. QDN reports serving as the Coordinating Investigator for the diabetic macular ischaemia and diabetic retinopathy programmes sponsored by Boehringer Ingelheim. He also serves on scientific advisory boards for Alumis, Boehringer Ingelheim, Genentech, Kriya Therapeutics, Priovant, Regeneron, Rezolute and Tourmaline. MG and NZ are employees of Boehringer Ingelheim.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}